Eisai Faces More Suits Tying Diet Drug Belviq to Cancer (1)

Eisai Pharmaceuticals Inc. and Arena Pharmaceuticals Inc. concealed cancer-related dangers of the now-withdrawn weight-loss drug Belviq, according to a new federal court suit by a New York woman who alleges it caused her thyroid cancer.

The drugmakers face other litigation linking cancer to its weight-loss drug, including a proposed class suit alleging its medical risks outweigh its benefits.

Deborah Steinman used Belviq from November 2014 through February 2017, along with a reduced-calorie diet and increased physical activity for chronic weight management, her complaint in the U.S. District Court for the Eastern District of New York says. Steinman’s thyroid cancer was ...